- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05585697
Bone Turnover in Type 2 Diabetes and Non-diabetes Controls (DiaMarv) (DiaMarv)
Markers of Bone Turnover and Advanced Glycation End Products Measured in the Circulation, Bone Marrow, and Bone Tissue in Individuals With and Without Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
3.1 Methods Study 1 is a cross-sectional study in which 26 individuals with T2D and 26 age matched individuals without T2D are examined. The investigators aim to investigate whether a) bone turnover markers are lower in individuals with type 2 diabetes (T2D) compared to persons without T2D based on circulating bone turnover markers, bone turnover markers in the bone marrow and bone turnover measured in bone tissue biopsies b) the levels of advanced glycation end-products (AGEs) in the circulation, bone marrow, bone tissue, and skin in individuals with and without T2D. The investigators hypothesize that the levels of AGEs is lower in all three tissue compartments in individuals with T2D compared to persons without T2D.
The individuals are included and recruited from outpatient clinics, general practitioners, letters based on information from national registries and via media advertisements.
Inclusion criteria for individuals with T2D; physician diagnosed T2D, diabetes duration ≥5 years, HbA1c ≥ 59 mmol/mol through the last 2 years, male gender, age > 40 years, and BMI < 35 kg/m2. Inclusion criteria for individuals without T2D; no diagnosis of T2D, male gender, age > 40 years, and BMI < 35 kg/m2. Exclusion criteria for all participants; trombocyte count < 100, treatment with anticoagulants except acetylic acids, renal impairment (eGFR <50 ml/min), bone metabolic disease, vitamin D insufficiency, treatment with antiosteoporotic agents or systemic glucocorticoids, and tetracycline allergy.
3.11 Methods Fasting morning blood samples will be collected. The participants will undergo a whole body dual energy x-ray absorptiometry (DXA) to investigate body composition (lean and fat mass) and a Jamshidi bone marrow biopsy in which two pieces of bone tissue is collected for measurement of bone turnover and AGES.
3.12. Bone tissue biopsy Before the bone tissue sampling, the bone tissue will be labelled twice by administration of tetracycline. Tetracykline is incorporated in newly formed bone as bands that are visible in a microscope. A histomorphometric analysis is conducted on the bone tissue sample to investigate the indices of bone turnover.
3.13 Measurement of biomarkers From the bone marrow and plasma/serum samples the following is measured Bone resorption markers: CTX and TRAP5b. Bone formation markers: P1NP, Osteocalcin, and Bone specific alkaline phosphatase.
Bone signaling markers: Osteoprotegerin, RANKL, Sclerostin and parathyroid hormone.
3.14. Analysis of the whole body DXA The whole body DXA measures BMD and lean and fat mass. 3.15 Measurement of AGEs Blood serum and bone marrow serum levels of AGEs are measured. For each participant, one bone tissue biopsy is pulverized, and the level of AGEs in the bone tissue estimated by Fourier Transformed Infrared Spectroscopy (FTIR) in collaboration with the Interdisciplinary Nanoscience Center, Aarhus University. Skin autofluorescence will be applied to non-invasively measure levels of AGEs in the skin.
3.16 Statistics Students t-tests will be used to compare levels of bone turnover markers and AGEs between individuals with and without T2D. Bland Altman plots will be used to analyze agreement between measurement of the bone turnover markers and AGEs at the different tissue compartments. Adjustment will be performed using logistic or linear regression dependent on data distribution.
3.1.7 Power calculation The power calculation is based on the bone formation marker, osteocalcin. Plasma osteocalcin levels were in a previous study 14,4 +/- 5,3 ug/l (mean+/-SD).
It is expected that tere will be a 30% lower level of osteocalcin in individuals with T2D compared to individuals without T2D. Based on the above assumptions, the probability of a type 1 error of 0.05, the probability of a type II error of 0.8, and that two marrow aspirations in each group will fail, 26 individuals should be included in each group in order to detect a difference.
3.l.8 Approval The study is approved at the Regional Ethics Committee, Region Midtjylland: 1-10-72-214-21.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aarhus N, Denmark, 8200
- Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion criteria for individuals with T2D;
- physician diagnosed T2D,
- diabetes duration ≥5 years,
- HbA1c ≥ 48 mmol/mol through the last 2 years
- male gender,
- age > 40 years
- BMI < 35 kg/m2
Inclusion criteria for individuals without T2D;
- no diagnosis of T2D
- male gender,
- age > 40 years
- BMI < 35 kg/m2
Exclusion Criteria:
- trombocyte count < 100
- treatment with anticoagulants except acetylic acids,
- renal impairment (eGFR <50 ml/min),
- bone metabolic disease
- vitamin D insufficiency
- treatment with antiosteoporotic agents
- Treatment with systemic glucocorticoids
- Tetracycline allergy.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Type 2 diabetes or control
Individuals with type 2 diabetes.
Expect to include 26.
Individuals without type 2 diabetes.
Expect to include 26.
|
None - crossectional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of Osteocalcin
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of CTX
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Plasma concentration of P1NP
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Plasma concentration of Sclerostin
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Bone marrow serum concentration of P1NP
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Bone marrow serum concentration of CTX
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Bone marrow serum concentration of Osteocalcin
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
Bone marrow serum concentration of Sclerostin
Time Frame: 2 years
|
Circulating bone turnover marker
|
2 years
|
serum concentration of penstosidine
Time Frame: 2 years
|
Advanced glycation endproduct
|
2 years
|
bone marrow serum concentration of pentosidine
Time Frame: 2 years
|
Advanced glycation endproduct
|
2 years
|
Bone formation rate in bone tissue
Time Frame: 2 years
|
Bone turnover in bone based on histomorphometric analysis
|
2 years
|
Advanced glycation endproductsproducts in bone
Time Frame: 2 years
|
Raman spectroscopy to determine levels of Advanced glycation endproducts in bone tissue
|
2 years
|
Strenght measure of bone
Time Frame: 2 years
|
Nano-indentation of the bone
|
2 years
|
trabecular separation distance
Time Frame: 2 years
|
bone structure measure provided by x-ray nano-CT
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUH_HOK_2022_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on None - crossectional
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingCoagulation Disorder | Endocarditis | Valve Disease, HeartNetherlands
-
University of OxfordCompleted
-
University of Campania "Luigi Vanvitelli"CompletedBirth Weight | Systemic Inflammation Markers | Combined Systemic Inflammatory IndicesItaly
-
Eunice Kennedy Shriver National Institute of Child...New York State Department of Health; University at AlbanyCompletedObesity | Asthma | Blood Pressure | Developmental Delay | Allergies | Motor Delay
-
Austin HealthCompletedReflux, Gastroesophageal | Colon Disease | Colon Polyp | Varices, EsophagealAustralia
-
University of GiessenCompleted
-
Affiliated Hospital of Nantong UniversityNot yet recruiting
-
Bursa Yüksek İhtisas Education and Research HospitalRecruitingPneumonia, Viral | COVID-19 Pneumonia | EGFR AmplificationTurkey
-
Peking University First HospitalActive, not recruitingSARS-CoV-2 Infection | Hematologic MalignancyChina
-
Acibadem UniversityCompleted